Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824315 | 0.74 | CA12 (0.42) | MAOAMAOBTSHRCES1BCHE | |
| SCHEMBL57213 | 0.74 | CA12 (0.42) | MAOAMAOBTSHRCES1BCHE | |
| Hydrochloric Acid SCHEMBL2455497 | 0.72 | CA12 (0.41) | MAOAMAOBTSHRCES1BCHE | |
| Hydrochloric Acid SCHEMBL7005883 | 0.72 | CA12 (0.41) | MAOAMAOBTSHRCES1BCHE | |
| SCHEMBL3099042 | 0.72 | CA12 (0.41) | MAOAMAOBTSHRCES1BCHE | |
| SCHEMBL7614336 | 0.69 | MAOA (0.33) | MAOAMAOBCES1BCHE | |
| SCHEMBL7825908 | 0.69 | MAOA (0.38) | MAOAMAOBLMNASMN1; SMN2CES1 | |
| SCHEMBL10640017 | 0.69 | ALDH1A1 (0.42) | MAOALMNACES1HPGDL3MBTL1 | |
| SCHEMBL9829828 | 0.68 | TSHR (0.43) | MAOAMAOBLMNASMN1; SMN2TSHR | |
| SCHEMBL60763 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1722796-A4 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7217709-B2 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1722796-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | Inotek Pharmaceuticals Corporation (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1603567-A4 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1603567-A2 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005082079-A2 | TETRACYCLIC LACTAM DERIVATIVES AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005009398-A2 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040229895-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | TBC1D5, TBC1D15, BAD | MAOA 1772/4885MAOB 1598/4885LMNA 1926/4885 |
| US-20050261288-A1 | Tetracyclic lactam derivatives and uses thereof | PARK7, GLS, IAPP | MAOA 1862/4885MAOB 2119/4885LMNA 4269/4885 |
| US-20040229895-A1 | Tetracyclic benzamide derivatives and methods of use thereof | TBC1D5, TBC1D15, BAD | MAOA 1772/4885MAOB 1598/4885LMNA 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.